Impact Biomedical (IBO) Operating Expenses (2022 - 2026)

Impact Biomedical (IBO) has reported Operating Expenses for 5 consecutive years, with $705000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 39.22% year-over-year to $705000.0; the trailing twelve-month figure through Jun 2026 stood at $3.5 million (down 88.06% YoY), and the FY2025 full-year result was $318000.0, down 98.89% from the prior year.
• Operating Expenses slipped to $705000.0 in Q2 2026 per IBO's latest filing, from $2.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $26.2 million in Q4 2024 and bottomed at -$441000.0 in Q4 2025.
• Historically, Operating Expenses has averaged $2.4 million across 5 years, with a median of $1.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 2202.99% in 2024, then slumped 101.68% in 2025.
• Over 5 years, Operating Expenses stood at $1.0 million in 2022, then advanced by 10.37% to $1.1 million in 2023, then jumped by 2202.99% to $26.2 million in 2024, then plunged by 101.68% to -$441000.0 in 2025, then soared by 259.86% to $705000.0 in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $705000.0, $2.3 million, and -$441000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.